Research digest / within-class comparison
CJC-1295 vs Sermorelin: Two GHRH Analogs on the GH/IGF-1 Axis
Same receptor, same axis, different clocks — what separates the long-acting analog from its short-acting class-mate.
The same receptor, a different clock
CJC-1295 vs sermorelin is a comparison within one drug class. Both are GHRH-receptor agonists — synthetic analogs of the GHRH(1-29) sequence that stimulate the pituitary to release the body's own growth hormone, raising IGF-1 downstream [8]. Sermorelin is essentially synthetic GHRH(1-29) itself; CJC-1295 is that backbone modified for resistance and, in the DAC form, for duration [2][8].
The defining difference is half-life. Sermorelin is short-acting, cleared in minutes, with an effect that tracks the natural pulse. CJC-1295 DAC is long-acting, with a 5.8-8.1 day half-life and IGF-1 elevation persisting up to 28 days after multiple doses [1]. They occupy the same axis through the same receptor — they differ chiefly in how long the signal lasts, which is a pharmacokinetic distinction, not a difference in target.
Where CJC-1295 sits among GHRH analogs
The class is small and well-characterized. It includes sermorelin (synthetic GHRH(1-29)), tesamorelin (the FDA-approved GHRH analog for HIV-associated lipodystrophy), and CJC-1295 (a research-stage long-acting analog) [8]. A 2025 Nature Reviews Endocrinology review describes the receptor signaling and the rationale for long-acting analog design across this class [8]. CJC-1295's position is defined by duration: it is the long-acting member, distinguished from sermorelin by the DAC albumin-conjugation strategy and from tesamorelin by its lack of regulatory approval for any indication.
What the comparison can and cannot claim
The pharmacology is comparable; the evidence base is not symmetric. Sermorelin has a long clinical history and was an approved diagnostic and therapeutic agent; CJC-1295 has only early-phase PK studies and no completed efficacy program [1]. So while both act on the GH/IGF-1 axis, a head-to-head efficacy or safety comparison in healthy adults does not exist in the published literature. The honest comparison is mechanistic and kinetic — same receptor, different duration — not a ranked outcome.
The long-acting profile is a double-edged property. Sustained GHRH-receptor stimulation produces durable IGF-1 elevation [1], but it also means a single dose cannot be quickly reversed, which is part of why sustained GH/IGF-1 elevation carries the theoretical safety questions discussed on the FAQ.
The pulsatility question
A reasonable concern about any long-acting GHRH analog is whether continuous stimulation flattens the natural GH pulse. For CJC-1295, the published answer is that it does not: in healthy men, the frequency and magnitude of pulsatile GH secretion were unaltered after a single dose, even as basal and mean GH rose [3]. This is biologically notable because episodic GHRH delivery drives GH pulses more effectively than continuous infusion [6] — so a long-acting analog that preserves pulsatility behaves more favorably than a naive continuous-stimulation model would predict. Sermorelin, being short-acting, tracks the natural pulse by default, so the two reach a similar pulsatile endpoint by different routes.
Which questions the comparison answers
For a reader deciding what the literature actually supports, the comparison resolves to a few clean facts. Both compounds act on the GHRH receptor and raise GH and IGF-1 [1][8]. CJC-1295 DAC does so for days from one dose; sermorelin does so briefly [1][2]. Neither has a head-to-head trial against the other. And one of the two — sermorelin — has regulatory history, while CJC-1295 remains unapproved for human use, a status detailed on the FAQ. Anything beyond those facts is extrapolation the published record does not license.